Lanean...
Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
Dasatinib and other tyrosine kinase inhibitors are commonly utilized in the management of chronic myelogenous leukemia. Pulmonary hypertension is an important adverse event associated with dasatinib. Mechanisms for pulmonary hypertension include pulmonary endothelial injury, apoptosis, and increased...
Gorde:
| Argitaratua izan da: | Pulm Circ |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6664660/ https://ncbi.nlm.nih.gov/pubmed/31274047 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894019865704 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|